Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.
Joussen AM, Wolf S, Kaiser PK, Boyer D, Schmelter T, Sandbrink R, Zeitz O, Deeg G, Richter A, Zimmermann T, Hoechel J, Buetehorn U, Schmitt W, Stemper B, Boettger MK. Joussen AM, et al. Among authors: zeitz o. Br J Clin Pharmacol. 2019 Feb;85(2):347-355. doi: 10.1111/bcp.13794. Epub 2018 Nov 25. Br J Clin Pharmacol. 2019. PMID: 30341774 Free PMC article. Clinical Trial.
Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Korobelnik JF, et al. Among authors: zeitz o. Ophthalmology. 2014 Jan;121(1):202-208. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084497 Free article. Clinical Trial.
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Schmidt-Erfurth U, et al. Among authors: zeitz o. Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084500 Clinical Trial.
Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Korobelnik JF, et al. Among authors: zeitz o. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8. Ophthalmology. 2014. PMID: 25012934 Clinical Trial.
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Ogura Y, et al. Among authors: zeitz o. Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25. Am J Ophthalmol. 2014. PMID: 25068637 Clinical Trial.
Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH, Boyer DS, Schmidt-Erfurth U, Heier JS, Gordon C, Benz MS, Marcus DM, Sabates NR, Vitti R, Kazmi H, Berliner AJ, Soo Y, Zhu X, Moini H, Zeitz O, Sandbrink R, Do DV. Gonzalez VH, et al. Among authors: zeitz o. Retina. 2015 Apr;35(4):687-94. doi: 10.1097/IAE.0000000000000430. Retina. 2015. PMID: 25621943 Clinical Trial.
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF. Brown DM, et al. Among authors: zeitz o. Ophthalmology. 2015 Oct;122(10):2044-52. doi: 10.1016/j.ophtha.2015.06.017. Epub 2015 Jul 18. Ophthalmology. 2015. PMID: 26198808 Clinical Trial.
Scheduled versus Pro Re Nata Dosing in the VIEW Trials.
Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, Norenberg C, Sandbrink R, Zeitz O. Richard G, et al. Among authors: zeitz o. Ophthalmology. 2015 Dec;122(12):2497-503. doi: 10.1016/j.ophtha.2015.08.014. Epub 2015 Oct 21. Ophthalmology. 2015. PMID: 26477840 Clinical Trial.
112 results